Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung.

Literature DB >> 28502722

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung.

Zhigang Yuan¹, Allison Fromm¹, Kamran A Ahmed¹, George D Grass¹, George Q Yang¹, Daniel E Oliver¹, Thomas J Dilling¹, Scott J Antonia², Bradford A Perez³.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Nivolumab

Year: 2017 PMID： 28502722 DOI： 10.1016/j.jtho.2017.04.029

Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

Review 1. [Combining radiotherapy with immunotherapy for urological malignancies].

Authors: S Rieken; R El Shafie
Journal: Urologe A Date: 2018-11 Impact factor: 0.639

Review 2. Radiotherapy and Immunotherapy Combinations for Lung Cancer.

Authors: Vishesh Agrawal; Kimberly Thomas Benjamin; Eric C Ko
Journal: Curr Oncol Rep Date: 2020-11-19 Impact factor: 5.075

Review 3. Development of Immunotherapy Combination Strategies in Cancer.

Authors: Timothy A Yap; Eileen E Parkes; Weiyi Peng; Justin T Moyers; Michael A Curran; Hussein A Tawbi
Journal: Cancer Discov Date: 2021-04-02 Impact factor: 39.397

Review 4. Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.

Authors: Chen Chen; Yanlong Liu; Binbin Cui
Journal: Hum Vaccin Immunother Date: 2021-01-11 Impact factor: 3.452

Review 5. Radiotherapy and checkpoint inhibitors: a winning new combination?

Authors: Eric C Ko; Silvia C Formenti
Journal: Ther Adv Med Oncol Date: 2018-04-11 Impact factor: 8.168

6. Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy.

Authors: Ioannis M Koukourakis; Axiotis G Giakzidis; Maria Kouroupi; Alexandra Giatromanolaki; Ioannis Abatzoglou; Antonios Karpouzis; Michael I Koukourakis
Journal: BJR Case Rep Date: 2021-02-04

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung.

Review 1. [Combining radiotherapy with immunotherapy for urological malignancies].

Review 2. Radiotherapy and Immunotherapy Combinations for Lung Cancer.

Review 3. Development of Immunotherapy Combination Strategies in Cancer.

Review 4. Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.

Review 5. Radiotherapy and checkpoint inhibitors: a winning new combination?

6. Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy.

Review 7. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.

Review 8. Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.

Review 9. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

Review 10. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.